CytoDyn
Vancouver, Washington, United States · Biotechnology, Healthcare, Health Care
CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. The CCR5 receptor is a protein located on the surface of various cells including white blood cells, stellate cells which produce scar tissue in the liver, cells that undergo malignant transformation,
Key facts
- Headquarters
- Vancouver, Washington, United States
- Employees
- 21
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (CYDY)
- Website
- cytodyn.com
- Company page
Recent activity at CytoDyn
- : CytoDyn Inc. Appoints Robert E. Hoffman as CEO
- : SEC 8-K (5.02): On October 16, 2026, CytoDyn Inc. appointed Robert E. Hoffman as the new Chief Executive Officer, effective October 20, 2026, following the resignation of Jacob P. Lalezari from the position of CEO on the same date. Dr. Lalezari will transition to a non-executive role as Head of Research and Translational Sciences. Mr. Hoffman, who has extensive experience in financial leadership roles in the biotechnology sector, has served as the Company’s Chief Financial Officer since May 15, 2025, and continues his duties as principal accounting officer. This management change signals a strategic shift in leadership at CytoDyn, potentially aligning with the company’s future operational and financial strategies.
- : CytoDyn Inc. has closed $16.5 million in financing to support the development of leronlimab. This funding reflects strong investor confidence in the company's clinical progress.
- : CytoDyn
- : SEC 8-K (7.01): On April 30, 2026, CytoDyn Inc. announced an investor call and webcast to provide a corporate and clinical update, with the event scheduled for the same day at 1:00 p.m. Pacific Time. The instructions for accessing the call were included in a prior press release dated April 23, 2026. The filing includes presentation materials, identified as Exhibit 99.1, which will be available on the company's website. This update is aimed at informing shareholders and other stakeholders of current developments in the company's operations and potential impacts on future performance.
- : SEC 8-K (1.01): On March 24, 2026, the Company entered into a material definitive agreement with the holders of secured convertible promissory notes (Note 1 and Note 2), extending the maturity dates of both notes by 36 months to April 5, 2029, and April 23, 2029, respectively. In return for this extension, the Company will make monthly payments of $1,000,000 in shares of common stock to the Noteholders, which will be calculated based on their respective stock prices prior to payment. The annual interest rate on each note has been reduced to 5%. This agreement is significant as it provides the Company with additional time to manage its financial obligations while adjusting payment structures to benefit both the Company and the Noteholders.
- : SEC 8-K (8.01):
- : SEC 8-K (1.01): On November 3, 2025, CytoDyn Inc. entered into a Standby Equity Purchase Agreement with YA II PN, Ltd., a Cayman Islands exempt limited partnership. This agreement allows CytoDyn to sell shares of its common stock to Yorkville over a 36-month period, with Yorkville obligated to purchase these shares at 98% of the lowest daily volume-weighted average price (VWAP) during a three-day pricing period starting from the notice date each time the company opts to execute a sale. The inclusion of such terms indicates the potential for significant capital infusion, assisting CytoDyn in financing its operations. This strategic agreement highlights a proactive approach to equity financing amid business developments.
- : SEC 8-K (1.01): On November 3, 2025, CytoDyn Inc. entered into a Standby Equity Purchase Agreement with YA II PN, Ltd. This agreement allows CytoDyn to sell shares of its common stock to Yorkville over a 36-month period, with conditions on pricing based on the volume weighted average price during specified trading days. While Yorkville will be required to purchase shares, there are restrictions ensuring it does not own more than 4.99% of CytoDyn's shares. A key condition for this agreement is that CytoDyn files and obtains effectiveness of a registration statement with the SEC regarding the resale of the stock involved. This agreement could provide CytoDyn with up to $30 million in capital, enhancing its financial flexibility for future operations.
- : CytoDyn Appoints Robert E. Hoffman as Chief Financial Officer
CytoDyn funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Venture | $16.5M |
| May 2026 | Venture | $18.6M |
| Sep 2022 | Venture | $21.8M |
| Apr 2022 | Seed | $1.9M |
| Apr 2022 | Seed | $1.9M |
Leadership
- Minxiu Chen, Director
- Scott Kelly, Executive Officer, Director
- Karen Brunke, Director
- Lishomwa Ndhlovu, Director
- Jordan Naydenov, Director
- Tanya Urbach, Director
- Scott Kelly, Executive Officer, Director
- Nader Pourhassan, Executive Officer, Director
- Harish Seethamraju, Director
- Jordan Naydenov, Director
- Lishomwa Ndhlovu, Director
- Tanya Urbach, Director
Verified email and direct lines for CytoDyn’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
CytoDyn files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
CytoDyn in the news
- Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer - Yahoo Finance (Jun 04, 2026)
- CytoDyn’s leronlimab reaffirms HIV potential after combo treatment eradicates virus in infant macaques - Fierce Biotech (Aug 12, 2026)
- CytoDyn Starts Phase 2a Trial of Leronlimab in Early Alzheimer’s Disease - The Clinical Trial Vanguard (Jun 12, 2026)
- Leronlimab Shows Early Clinical and Biomarker Activity in Metastatic Colorectal Cancer at AACR 2026 - BioPharm International (Apr 22, 2026)
- CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th - GlobeNewswire (Sep 15, 2026)
- Natera (NTRA), CytoDyn Announce Strategic Collaboration for ctDNA-Guided mCRC Clinical Trials - Yahoo Finance (Jun 17, 2026)
- Former Portland-area biotech CEO is sentenced in securities fraud scheme - The Business Journals (Jan 26, 2026)
- Small Biotech Stock CytoDyn Soars on ‘Warp Speed’ Comment - WSJ (Aug 26, 2020)
Companies similar to CytoDyn
- BiomX · Biotechnology, Healthcare, Health Care, Therapeutics
- Oncotelic Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Ovid Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Tempest Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Galecto · Biotechnology, Healthcare, Health Care, Therapeutics
About CytoDyn: questions and answers
What does CytoDyn do?
CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. The CCR5 receptor is a protein located on the surface of various cells including white blood cells, stellate cells which produce scar tissue in the liver, cells that undergo malignant transformation,
Where is CytoDyn headquartered?
CytoDyn is headquartered in Vancouver, Washington, United States.
How many employees does CytoDyn have?
CytoDyn has about 21 employees.
Has CytoDyn raised funding?
Yes. Fundz has recorded 5 funding events for CytoDyn. The most recent, $16.5M, was in Sep 2026.
What is the latest news on CytoDyn?
On Oct 19, 2026, CytoDyn Inc. Appoints Robert E. Hoffman as CEO
Is CytoDyn a public company?
Yes. CytoDyn is publicly traded under the ticker CYDY.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy